Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Queen's University Belfast, Belfast, UK.
J Stuart
JS
Elborn
CW8-5B Center for Clinical and Translational Research, Seattle, Washington, USA.
Bonnie
B
Ramsey
Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia.
Claire
C
Wainwright
Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Michael
M
Boyle
D000627:Aminophenols / Q000627:therapeutic use*; D000631:Aminopyridines / Q000627:therapeutic use*; D052117:Benzodioxoles / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D017353:Gene Deletion; D006801:Humans; D015363:Quinolones / Q000627:therapeutic use*
D000627:Aminophenols; D000631:Aminopyridines; D052117:Benzodioxoles; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator
Cystic Fibrosis